MA39950B1 - Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie - Google Patents

Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie

Info

Publication number
MA39950B1
MA39950B1 MA39950A MA39950A MA39950B1 MA 39950 B1 MA39950 B1 MA 39950B1 MA 39950 A MA39950 A MA 39950A MA 39950 A MA39950 A MA 39950A MA 39950 B1 MA39950 B1 MA 39950B1
Authority
MA
Morocco
Prior art keywords
bladder
urinary tract
urinary
diseases
muscarinic
Prior art date
Application number
MA39950A
Other languages
English (en)
Other versions
MA39950A (fr
Inventor
Hiroaki Tanaka
Taisuke Takahashi
Takanori Koike
Kenji Negoro
Jun Maeda
Kazuhiro Yokoyama
Hajime Takamatsu
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MA39950A publication Critical patent/MA39950A/fr
Publication of MA39950B1 publication Critical patent/MA39950B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Le problème abordé par la présente invention est de pourvoir à un composé utile à titre de principe actif dans une composition pharmacologique destinée à traiter les symptômes du stockage urinaire, la dysurie, les maladies des voies urinaires inférieures, et autres. Les inventeurs ont perfectionné la présente invention après avoir découvert que des dérivés de thiazole substitués en position 2 par un pyrazinylcarbonylamino sont d'exceptionnels modulateurs allostériques positifs aux récepteurs muscariniques m3 et devraient pouvoir servir d'agents pour prévenir ou traiter les maladies de la vessie urinaire et des voies urinaires impliquant la contraction de la vessie médiée par les récepteurs muscariniques m3. Les dérivés de 2-acylaminothiazole ou leurs sels selon la présente invention devraient pouvoir servir d'agents pour prévenir ou traiter les maladies de la vessie urinaire et des voies urinaires impliquant la contraction de la vessie médiée par les récepteurs muscariniques m3, par exemple, une vessie hypoactive et autre.
MA39950A 2014-06-06 2015-06-05 Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie MA39950B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014118046 2014-06-06
EP15803484.3A EP3153511B1 (fr) 2014-06-06 2015-06-05 Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie
PCT/JP2015/066321 WO2015186821A1 (fr) 2014-06-06 2015-06-05 Dérivé de 2-acylaminothiazole ou sel de celui-ci

Publications (2)

Publication Number Publication Date
MA39950A MA39950A (fr) 2017-04-12
MA39950B1 true MA39950B1 (fr) 2019-08-30

Family

ID=54766887

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39950A MA39950B1 (fr) 2014-06-06 2015-06-05 Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie

Country Status (35)

Country Link
US (2) US9951060B2 (fr)
EP (1) EP3153511B1 (fr)
JP (1) JP6319436B2 (fr)
KR (1) KR102482844B1 (fr)
CN (2) CN106414438B (fr)
AR (1) AR100748A1 (fr)
AU (1) AU2015269449B2 (fr)
BR (1) BR112016028270B1 (fr)
CA (1) CA2950564C (fr)
CO (1) CO2017000044A2 (fr)
CY (1) CY1122290T1 (fr)
DK (1) DK3153511T3 (fr)
EA (1) EA031866B1 (fr)
ES (1) ES2732066T3 (fr)
HR (1) HRP20190943T1 (fr)
HU (1) HUE043496T2 (fr)
IL (1) IL249356B (fr)
LT (1) LT3153511T (fr)
MA (1) MA39950B1 (fr)
ME (1) ME03438B (fr)
MX (2) MX387775B (fr)
MY (1) MY197712A (fr)
NZ (1) NZ727142A (fr)
PH (1) PH12016502405A1 (fr)
PL (1) PL3153511T3 (fr)
PT (1) PT3153511T (fr)
RS (1) RS58809B1 (fr)
SA (1) SA516380427B1 (fr)
SG (2) SG11201610201UA (fr)
SI (1) SI3153511T1 (fr)
SM (1) SMT201900352T1 (fr)
TR (1) TR201908676T4 (fr)
TW (2) TWI689507B (fr)
UA (1) UA122208C2 (fr)
WO (1) WO2015186821A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079112A1 (fr) 2006-12-20 2008-07-03 Thomson Licensing Commutateur de routage audio intégré
CN106573928B (zh) 2014-08-26 2020-04-14 安斯泰来制药株式会社 2-氨基噻唑衍生物或其盐
US10633341B2 (en) 2016-12-19 2020-04-28 Novartis Ag Picolinic acid derivatives and their use as intermediates
JPWO2019189766A1 (ja) * 2018-03-30 2021-04-08 持田製薬株式会社 新規ビアリールアミド誘導体
PT3792260T (pt) 2018-05-08 2024-10-02 Nippon Shinyaku Co Ltd Compostos de azabenzimidazol e produtos farmacêuticos
CN111718293A (zh) * 2019-03-18 2020-09-29 持田制药株式会社 双芳基酰胺衍生物的制造方法
CA3161582A1 (fr) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Compose azabenzimidazole et medicament
EP3967311A1 (fr) * 2020-09-11 2022-03-16 Astellas Pharma Inc. Composés destinés à être utilisés dans le traitement de la sécheresse buccale
WO2024122076A1 (fr) 2022-12-09 2024-06-13 株式会社旭飛薬業 Agent de régulation de fluide corporel, agent d'association pour la régulation de fluide corporel et utilisation d'un composé

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
JP2001278872A (ja) * 2000-03-27 2001-10-10 Banyu Pharmaceut Co Ltd 新規アミノチアゾール誘導体
IL152701A0 (en) * 2000-05-25 2003-06-24 Hoffmann La Roche Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
EP1452525A4 (fr) * 2001-10-30 2005-01-26 Nippon Shinyaku Co Ltd Derives amide, et medicaments correspondants
JP4120586B2 (ja) * 2002-01-18 2008-07-16 アステラス製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
TWI242478B (en) 2002-08-01 2005-11-01 Masami Nakamoto Metal nanoparticle and process for producing the same
TW200410951A (en) * 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
MXPA06000441A (es) 2003-07-17 2006-04-05 Astellas Pharma Inc Derivado de 2-acilaminotiazole o sal del mismo.
JP4665769B2 (ja) 2005-01-12 2011-04-06 アステラス製薬株式会社 アシルアミノチアゾール誘導体の製造法
JP4774995B2 (ja) 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
CN101490003A (zh) * 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
EP2206707B1 (fr) 2007-10-24 2014-07-23 Astellas Pharma Inc. Composé à base d'azolecarboxamide ou son sel
PE20130774A1 (es) * 2010-07-29 2013-06-26 Rigel Pharmaceuticals Inc Compuestos heterociclicos activadores de ampk y metodos para emplearlos
TWI647227B (zh) 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽

Also Published As

Publication number Publication date
NZ727142A (en) 2022-10-28
ES2732066T3 (es) 2019-11-20
US20170197955A1 (en) 2017-07-13
TWI689507B (zh) 2020-04-01
PH12016502405B1 (en) 2017-02-20
CY1122290T1 (el) 2021-01-27
EA031866B1 (ru) 2019-03-29
UA122208C2 (uk) 2020-10-12
SG10202000463YA (en) 2020-02-27
AR100748A1 (es) 2016-10-26
TR201908676T4 (tr) 2019-07-22
SI3153511T1 (sl) 2019-08-30
CA2950564C (fr) 2023-03-07
US9951060B2 (en) 2018-04-24
CA2950564A1 (fr) 2015-12-10
ME03438B (fr) 2020-01-20
EP3153511B1 (fr) 2019-05-15
TWI745877B (zh) 2021-11-11
HUE043496T2 (hu) 2019-08-28
PT3153511T (pt) 2019-06-28
CN106414438A (zh) 2017-02-15
SG11201610201UA (en) 2017-01-27
RS58809B1 (sr) 2019-07-31
BR112016028270B1 (pt) 2023-05-02
BR112016028270A8 (pt) 2023-01-17
BR112016028270A2 (pt) 2022-07-19
TW201613914A (en) 2016-04-16
MX370140B (es) 2019-12-03
LT3153511T (lt) 2019-07-10
MY197712A (en) 2023-07-09
CN110845490A (zh) 2020-02-28
PH12016502405A1 (en) 2017-02-20
KR102482844B1 (ko) 2022-12-30
CN106414438B (zh) 2019-12-31
IL249356A0 (en) 2017-02-28
TW202026294A (zh) 2020-07-16
JPWO2015186821A1 (ja) 2017-04-20
EP3153511A4 (fr) 2017-12-06
MX2016016134A (es) 2017-03-08
IL249356B (en) 2019-11-28
KR20170013987A (ko) 2017-02-07
DK3153511T3 (da) 2019-06-24
PL3153511T3 (pl) 2019-09-30
HRP20190943T1 (hr) 2019-09-20
AU2015269449B2 (en) 2019-03-14
EA201692469A1 (ru) 2017-05-31
WO2015186821A1 (fr) 2015-12-10
CN110845490B (zh) 2023-03-28
MX387775B (es) 2025-03-18
CO2017000044A2 (es) 2017-03-31
MA39950A (fr) 2017-04-12
SMT201900352T1 (it) 2019-07-11
SA516380427B1 (ar) 2019-11-28
EP3153511A1 (fr) 2017-04-12
JP6319436B2 (ja) 2018-05-09
AU2015269449A1 (en) 2016-12-22
USRE49111E1 (en) 2022-06-21

Similar Documents

Publication Publication Date Title
MA39950B1 (fr) Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie
ECSP19053616A (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
BR112015009850A2 (pt) compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
ECSP20035588A (es) Derivado de amino-metil piperidina como inhibidor de quinasa
AR099489A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MA39427A1 (fr) Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
EA201790818A1 (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
MY190361A (en) 2-acylaminothiazole derivative or salt thereof
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
BR112021016912A2 (pt) Composto de benzoindazolona e intermediário do mesmo
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
TR201908031T4 (tr) İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu.
AR105400A1 (es) Inhibidores de jak1
BR112016027729A2 (pt) Composto derivado de piridina, composição farmacêutica contendo o referido composto e seu uso